Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05073835 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Semaglutide 2.4 mg in Patients With Poor Weight-loss

Study acronym: BARI-STEP
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 6, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 2025 to Mar 2025v4
  2. Primary completion date: Mar 2024 to Sep 2025v3 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: May 2024 to Sep 2025
    • Eligibility criteria revised
    • Study site revised
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Jan 2022 to Nov 1, 2022
    • Primary completion date: Sep 2023 to Mar 2024
    • Study completion date: Nov 2023 to May 2024
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University College, London
186 trials monitored
See 4 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
A double-blinded, randomised, placebo-controlled trial of semaglutide 3.0 mg/ml in patients with poor weight-loss following bariatric surgery. The primary aim of this trial is to determine whether, and the extent to which, 68 weeks of subcutaneous semaglutide 3.0 mg/ml causes greater percentage weight loss (%WL), reduction in adiposity, improvement in metabolic and inflammatory indices and health-related quality of life (HRQoL) than placebo, in patients with poor weight loss following gastric bypass or sleeve gastrectomy.
Trial Details
NCT Number NCT05073835
Lead Sponsor University College, London
Conditions
(from sponsor)		 Obesity, Diabetes, Metabolic Syndrome
Related terms Diabetes Mellitus, Metabolic Syndrome, Obesity
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov